A Phase 3 interventional study of Eculizumab and Placebo in Refractory Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 60 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2014, is one of 9 in phase 3, and was the 3rd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 18+
AstraZeneca · Sites in Russia
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Italy
Ages 18+
AstraZeneca · Sites in Poland
Ages 18+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2014.
This study's enrollment of 117 is above the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 20 across the 13 interventional studies, 263 across the 6 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
4 of the studies in Myasthenia Gravis by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT07596784Phase 3Alexion Pharmaceuticals, Inc.Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | 2027-08-24 |
| NCT06967480Alexion Pharmaceuticals, Inc.Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | 2027-06-30 |
| NCT07221838Alexion Pharmaceuticals, Inc.A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | 2027-08-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
ECU-MG-302 was an extension study designed to provide the participants who completed Study ECU-MG-301 an opportunity to receive eculizumab and collect clinical data to provide long-term safety and efficacy information on eculizumab in participants with refractory gMG.
After receiving blinded study treatment (eculizumab or placebo) in Study ECU-MG-301 for 26 weeks, participants were eligible to enroll in the ECU-MG-302 extension study. Participants were to enter Study ECU-MG-302 within 2 weeks after completing their Week 26 visit in Study ECU-MG-301.
Study ECU-MG-302 consisted of a 4-week Blind Induction Phase to preserve the blinded nature of Study ECU-MG-301, an Open-Label Maintenance Phase (up to 4 years), and a Safety Follow-up visit 8 weeks after the last dose for participants who withdrew from the study or discontinued eculizumab treatment at any time and for any reason after receiving any amount of eculizumab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams \[mg\]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3. Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study. Eculizumab 1200 mg was administered for up to 4 years in this extension study.
Biological: Eculizumab · Drug: Placebo
Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3. Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study. Eculizumab 1200 mg was administered for up to 4 years in this extension study.
Biological: Eculizumab · Drug: Placebo
Intravenous administration of eculizumab.
Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
Count Of Participants With Treatment-Emergent Adverse Events
Treatment-emergent adverse events (TEAEs) are adverse events with onset on or after the first study drug dose in Study ECU-MG-302. Likewise, treatment-emergent serious adverse events (TESAEs) are serious adverse events that onset on or after the first study drug dose in Study ECU-MG-302. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Day 1 (after dosing) through End of Study (Week 208)
Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score At Week 4 And Week 130
The MG-ADL scale is a validated 8-item patient-reported outcome measure. Participants assessed their functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb impairment (2 items). These 8 items were not weighted and were individually graded from 0 (normal) to 3 (most severe), providing a total MG-ADL score ranging from 0 to 24 points. A reduction in score indicates improvement in condition. Baseline was defined as the last available assessment prior to treatment (first study drug infusion) with eculizumab in Study ECU-MG-302. Change from Baseline in MG-ADL total score at Week 4 (blind induction phase) and at Week 130 (open-label eculizumab phase) are presented.
Time frame: Baseline, Week 4 and Week 130
Participants who completed Study ECU-MG-301 (NCT01997229) were eligible to participate in Study ECU-MG-302.
| Milestone | Eculizumab/Eculizumab | Placebo/Eculizumab |
|---|---|---|
| Started | 56 | 61 |
| Received at least 1 dose of study drug | 56 | 61 |
| Completed | 55 | 61 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Eculizumab/Eculizumab | Placebo/Eculizumab |
|---|---|---|
| Started | 55 | 61 |
| Received at least 1 dose of study drug | 55 | 61 |
| Completed | 43 | 44 |
| Not completed | 12 | 17 |
| Withdrew: Withdrawal by subject | 4 | 8 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Physician decision | 3 | 3 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Participant felt no change in condition | 1 | 0 |
Treatment-emergent adverse events (TEAEs) are adverse events with onset on or after the first study drug dose in Study ECU-MG-302. Likewise, treatment-emergent serious adverse events (TESAEs) are serious adverse events that onset on or after the first study drug dose in Study ECU-MG-302. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Eculizumab/Eculizumab | Placebo/Eculizumab |
|---|---|---|
| TEAEs | 55 | 59 |
| TEAEs leading to withdrawal | 3 | 5 |
| TESAEs | 30 | 30 |
| TESAEs leading to withdrawal | 3 | 4 |
| Deaths | 2 | 1 |
The MG-ADL scale is a validated 8-item patient-reported outcome measure. Participants assessed their functional disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb impairment (2 items). These 8 items were not weighted and were individually graded from 0 (normal) to 3 (most severe), providing a total MG-ADL score ranging from 0 to 24 points. A reduction in score indicates improvement in condition. Baseline was defined as the last available assessment prior to treatment (first study drug infusion) with eculizumab in Study ECU-MG-302. Change from Baseline in MG-ADL total score at Week 4 (blind induction phase) and at Week 130 (open-label eculizumab phase) are presented.
| units on a scale | Eculizumab/Eculizumab | Placebo/Eculizumab |
|---|---|---|
| Change from Baseline At Week 4 (Blind Induction) | -0.2 ± 1.77 | -2.4 ± 3.04 |
| Change from Baseline at Week 130 (Open-label) | -0.7 ± 4.19 | -3.9 ± 3.68 |
Collected over Day 1 after dosing of study drug through Week 208.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab/Eculizumab | 2/56 (3.6%) | 30/56 (53.6%) | 54/56 (96.4%) |
| Placebo/Eculizumab | 1/61 (1.6%) | 30/61 (49.2%) | 59/61 (96.7%) |
| Eculizumab (Combined Total) | 3/117 (2.6%) | 60/117 (51.3%) | 113/117 (96.6%) |
| Event | Eculizumab/Eculizumab | Placebo/Eculizumab | Eculizumab (Combined Total) |
|---|---|---|---|
| Myasthenia gravisNervous system disorders | 7/56 | 9/61 | 16/117 |
| PyrexiaGeneral disorders | 3/56 | 0/61 | 3/117 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/18 | 1/20 | 1/38 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/56 | 3/61 | 3/117 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/56 | 3/61 | 3/117 |
| AnaemiaBlood and lymphatic system disorders | 2/56 | 1/61 | 3/117 |
| InfluenzaInfections and infestations | 2/56 | 0/61 | 2/117 |
| PneumoniaInfections and infestations | 2/56 | 2/61 | 4/117 |
| SepsisInfections and infestations | 2/56 | 1/61 | 3/117 |
| Humerus fractureInjury, poisoning and procedural complications | 2/56 | 0/61 | 2/117 |
| Event | Eculizumab/Eculizumab | Placebo/Eculizumab | Eculizumab (Combined Total) |
|---|---|---|---|
| HeadacheNervous system disorders | 20/56 | 24/61 | 44/117 |
| NasopharyngitisInfections and infestations | 20/56 | 22/61 | 42/117 |
| DiarrhoeaGastrointestinal disorders | 15/56 | 14/61 | 29/117 |
| Upper respiratory tract infectionInfections and infestations | 12/56 | 15/61 | 27/117 |
| Myasthenia gravisNervous system disorders | 12/56 | 5/61 | 17/117 |
| CoughRespiratory, thoracic and mediastinal disorders | 12/56 | 10/61 | 22/117 |
| NauseaGastrointestinal disorders | 9/56 | 13/61 | 22/117 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/56 | 12/61 | 23/117 |
| InfluenzaInfections and infestations | 11/56 | 10/61 | 21/117 |
| Urinary tract infectionInfections and infestations | 10/56 | 8/61 | 18/117 |
All eligible enrolled participants who received at least 1 dose of study drug in this extension study.
| Age, Continuous(years) | Eculizumab/Eculizumab | Placebo/Eculizumab | Total |
|---|---|---|---|
| Mean | 47.2 ± 15.52 | 47.5 ± 17.85 | 47.4 ± 16.70 |
| Sex: Female, Male(Participants) | Eculizumab/Eculizumab | Placebo/Eculizumab | Total |
|---|---|---|---|
| Female | 38 | 41 | 79 |
| Male | 18 | 20 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Eculizumab/Eculizumab | Placebo/Eculizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 10 | 18 |
| Not Hispanic or Latino | 45 | 48 | 93 |
| Unknown or Not Reported | 3 | 3 | 6 |
| Race/Ethnicity, Customized(Participants) | Eculizumab/Eculizumab | Placebo/Eculizumab | Total |
|---|---|---|---|
| Asian | 3 | 16 | 19 |
| Black or African American | 0 | 2 | 2 |
| White | 47 | 41 | 88 |
| Multiple | 1 | 0 | 1 |
| Unknown | 1 | 0 | 1 |
| Other | 4 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Jan 2019, 50 months.
Results were first posted in Feb 2020, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 50 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →